Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

fresenius kabi italia s.r.l. - lidocaina - lidocaina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sun pharmaceutical industries (europe) b.v. - irinotecan - irinotecan

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

medac gesellschaft fur klinische spezialpraparate mbh - irinotecan - irinotecan

Unione Europea - italiano - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - reiezione del trapianto - immunosoppressori - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

eg s.p.a. - diazepam - diazepam

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

aspen pharma trading limited - mivacurio cloruro - mivacurio cloruro

Italia - italiano - Ministero della Salute

izo s.r.l. a socio unico - calcio borogluconato, caffeina - calcio borogluconato - 20 grammo (i) ; caffeina - nd, caffeina - nd ; calcio borogluconato - 20 g, caffeina - 0.4 g; calcio borogluconato - 20 g - calcium, combinations with other drugs

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

noridem enterprises ltd - rocuronio bromuro - rocuronio bromuro

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

zeta farmaceutici spa - litio carbonato - compresse - 50 compresse 300 mg

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sella srl - litio carbonato - compresse - 50 compresse 300 mg